Masimo at a glance

Masimo (MASI) has been drawing attention after a period of strong year to date share performance, prompting investors to reassess how its current valuation lines up with its healthcare focused revenue base and profitability.

At a share price of $179.95, Masimo has recorded a 41.25% year to date share price return. The 1 year total shareholder return of 7.09% and 5 year total shareholder return decline of 19.88% present a mixed longer term picture, suggesting that recent momentum is building from a softer base.

If Masimo's recent move has you rethinking your healthcare exposure, it can be useful to compare it with other companies at the intersection of medicine and data, starting with 39 healthcare AI stocks

With Masimo trading close to its latest analyst price target and recent gains coming on top of solid reported revenue and net income growth, the key question is whether the stock is still attractively priced or already reflecting future growth.

Most Popular Narrative: Fairly Valued

Masimo's most followed narrative pegs fair value at $180, almost exactly in line with the last close at $179.95. This puts the spotlight on the assumptions behind that match.

Significant opportunities in wearable and telemonitoring solutions, currently in pilot phase, position the company to address the rising demand for at-home and remote patient monitoring, increasing Masimo's total addressable market and providing a new, recurring revenue source that will smooth earnings volatility from equipment sales.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that $180 fair value? The narrative leans heavily on steadier margins, measured revenue growth, and a future earnings multiple usually reserved for higher growth medtech stocks.

Result: Fair Value of $180 (ABOUT RIGHT)

However, there are still pressure points to watch, including tariff exposure on manufacturing in Malaysia, China, and Mexico, and the shift from equipment sales to lease based revenue. Both of these factors could challenge the fair value story if they affect margins or reported growth.

Another View: Rich Multiples vs Fair Value Story

That $180 fair value anchor sits awkwardly beside how the stock is actually priced on earnings. Masimo trades on a P/E of 43.5x, compared with 25.2x for the US Medical Equipment industry, 38.1x for peers, and a fair ratio of 26.1x that the SWS model points to.

In plain terms, the market is paying a premium that is well above both peers and that fair ratio. This could mean extra downside risk if sentiment cools, or simply a high bar for future execution. How comfortable are you with that gap?

Next Steps

With sentiment divided between rich multiples and a fair value story, it helps to move quickly, review the underlying data, and weigh both sides for yourself using our breakdown of 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Masimo has sharpened your thinking, do not stop here. Broaden your watchlist with other focused stock ideas that fit different roles in your portfolio.

• Target potential mispricing by scanning companies that combine quality fundamentals with appealing valuations using the 46 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses with higher yields and resilient payouts through the 9 dividend fortresses.
• Prioritise resilience by searching for companies with robust finances and dependable fundamentals via the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.